axicabtagene ciloleucel
gilead sciences,daiichi sankyo
['lymphoma', 'axicabtagene ciloleucel']
at the #asco22 clinical science symposium? read about the phase ii zuma-12 trial on axicabtagene ciloleucel as first line therapy for large b cell #lymphoma led by speaker sattva neelapu 
Nature Medicine is a research journal devoted to publishing the latest advances in translational and clinical research for scientists and physicians.